4-异丙基-6-甲基-3-吗啉酮 | 121923-44-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 4-异丙基-6-甲基-3-吗啉酮
• 英文名称: 6-Methyl-4-propan-2-ylmorpholin-3-one
• CAS: 121923-44-2
• 化学式: C₈H₁₅NO₂
• 分子量: 157.213
• InChiKey: WWICKIPMDQBQGQ-UHFFFAOYSA-N

物化性质

• 沸点：
  263.2±33.0 °C(Predicted)
• 密度：
  1.000±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  苯甲醛 、 4-异丙基-6-甲基-3-吗啉酮 在 lithium diisopropyl amide 作用下， 生成 2-<1-hydroxy-1-phenylmethyl>-4-isopropyl-6-methyl-3-morpholinone
  参考文献：
  名称：

  Dobrev, Alexander; Nechev, Ljubomir; Ivanov, Christo, Liebigs Annalen der Chemie, 1989, p. 815 - 818

  摘要：

  DOI：

文献信息

• Dobrev, Alexander; Nechev, Lubomir; Ivanov, Christo, Journal of Chemical Research, Miniprint, 1999, # 3, p. 1001 - 1047
  作者：Dobrev, Alexander、Nechev, Lubomir、Ivanov, Christo、Bon, Maryse

  DOI：——

  日期：——
• Dobrev, A.; Nechev, L. V.; Ivanov, C., Synthetic Communications, 1989, vol. 19, # 3and4, p. 613 - 618
  作者：Dobrev, A.、Nechev, L. V.、Ivanov, C.

  DOI：——

  日期：——
• DOBREV, A.;NECHEV, L. V.;IVANOV, C., SYNTH. COMMUN., 19,(1989) N-4, C. 613-617
  作者：DOBREV, A.、NECHEV, L. V.、IVANOV, C.

  DOI：——

  日期：——
• 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES
  申请人：Pharvaris GmbH

  公开号：US20220135542A1

  公开（公告）日：2022-05-05

  The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema. (I)